>
网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
C-erb B-2基因在肺癌中表达意义的临床研究
作者:朱晓莉 林勇 唐剑英 张祖贻 
单位:东南大学附属中大医院,呼吸科,江苏,南京,210009
关键词:C-erb B-2基因 肺癌 免疫组织化学 
分类号:R734.2
出版年·卷·期(页码):2006·25·第一期(41-43)
摘要:

目的:了解C-erb B-2基因在肺癌中表达的临床意义.方法:采用免疫组化方法检测42例各类型肺癌组织和10例正常肺组织中C-erb B-2基因的表达.结果:C-erb B-2基因在正常肺组织和小细胞肺癌中未见表达,在非小细胞肺癌组织中的表达率为25.71%,其中肺鳞癌表达率为6.3%,肺腺癌为50.0%,两者差异显著(P<0.05).C-erb B-2基因在不同组织学分级中的表达差异明显(P<0.05),低分化组为70%,中分化组为13.3%,高分化组为0.而在临床分期中的表达无显著性差异(P>0.05).结论:C-erb B-2基因在非小细胞肺癌特别是腺癌的形成和进展中发挥重要作用,C-erb B-2基因的检测可作为非小细胞肺癌患者选择个体化治疗方案的指标.

Objective To assess the clinical significance of the expression of C-erbB-2 oncogene in lung cancer.Methods Expression of C-erbB-2 was tested using immunohistochemistry method in 42 specimens of lung cancer and 10 samples of normal lung tissues.Results C-erbB-2 was unexpressed in normal lung tissues and small cell lung cancer.The rate of C-erbB-2 oncogene expression was 25.71% in non-small cell lung cancer(NSCLC).The positive rate of C-erbB2 oncogene differed according to histologic type,including 50.3% of patients with adenocarcinoma and 6.3% of patients with squamous cell carcinoma.Overexpression of C-erbB-2 in lung squamous cell carcinomas and adenocarcinomas had obvious difference((P<)(0.05)).The difference was also significant(P<0.05) among histologic grades Ⅰ,Ⅱ and Ⅲ being 70%,13.3%,0 respectively.There was no significant difference(P>0.05) among clinical stage Ⅰ,Ⅱ and Ⅲ.Conclusion The results suggest that C-erbB-2 may play an important role in the development and progression of NSCLC,especially in lung adenocarcinoma.The detection of C-erbB-2 may be helpful to select individualized therapy project for patients with NSCLC.

参考文献:

[1] 许良中, 朱雄增, 蒋国梁. 203例肺癌癌基因与抗癌基因蛋白的研究, 1994(4)
[2] HIRASHIMA N, TAKAHASHI W, YOSHII S. Protein overexpression and gene amplification of c-erbB-2 in pulmonary carcinomas:a comparative immunohistochemical and fluorescence in situ hybridization study. 2001(6). doi:10.1038/modpathol.3880350
[3] SCHNEIDER P M, PRAEUER H W, STOELTZING O. Multiple molecular marker testing (p53,C-Ki-ras,c-erbB-2)improves estimation of prognosis in potentially curative resected non-small cell lung cancer. 2000(4). doi:10.1054/bjoc.2000.1287
[4] KERN J A, ROBINSON R A, GAZDAR A. Mechanism of p185 HER-2 expression in human non-small cell lung cancer cell lines, 1992(4)
[5] HYNES N E, STERN D F. The biology of p185/neu/HER-2and its role in cancer, 1994(2)
[6] NAKAMURA H, KAWASAKI N, TAGUCHI M. Association of HER-2 overexpression with prognosis in nonsmall cell lung carcinoma:a metaanalysis. 2005(9). doi:10.1002/cncr.20957
[7] CANTERO R, TORRES A J, MAESTRO M L. Prognostic value of the quantified expression of p185 in non-small cell lung cancer, 2000(6)
[8] 朱晓莉, 林勇, 唐剑英. C-erb B-2基因在人肺腺癌细胞表达与药物治疗关系的研究. 现代医学2004(6). doi:10.3969/j.issn.1671-7562.2004.06.003
[9] HIRATA A, HOSOI F, MIYAGAWA M. HER2 overexpression increases sensitivity to gefitinib,an epidermal growth factor receptor tyrosine kinase inhibitor,through inhibition of HER2/HER3 heterodimer formation in lung cancer cells. 2005(10). doi:10.1158/0008-5472.CAN-04-2748 

服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 360651 位访问者


copyright ©《东南大学学报(医学版)》编辑部
联系电话:025-87232481 83272483
电子邮件:
bjb@pub.seu.edu.cn

苏ICP备09058364